Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now
The FDA is tapping the brakes on one of Adaptimmune T-cell studies, looking for some clarifications before it gives the green light to start testing NY-ESO SPEAR T-cell therapy in myxoid round cell liposarcoma.
No doubt there were a few skipped heart beats among investors, but the UK biotech $ADAP hurried on to explain that regulators are simply looking to get a few answers for a registration trial that has yet to start recruiting patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.